Myriad Genetics, Inc. (0K3W.L)
USD 7.62
(4.89%)
USD 7.62
(4.89%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2022 | 476.4 Million USD | -3.37% |
| 2021 | 493 Million USD | 30.15% |
| 2020 | 378.8 Million USD | -41.73% |
| 2019 | 650.1 Million USD | 0.0% |
| 2018 | 650.1 Million USD | 9.19% |
| 2017 | 595.4 Million USD | -0.8% |
| 2016 | 600.2 Million USD | 0.62% |
| 2015 | 596.5 Million USD | 3.61% |
| 2014 | 575.7 Million USD | -13.95% |
| 2013 | 669.01 Million USD | 25.39% |
| 2012 | 533.54 Million USD | 23.69% |
| 2011 | 431.34 Million USD | 21.38% |
| 2010 | 355.37 Million USD | 11.62% |
| 2009 | 318.36 Million USD | 12.39% |
| 2008 | 283.26 Million USD | -5.98% |
| 2007 | 301.28 Million USD | 138.53% |
| 2006 | 126.31 Million USD | 45.8% |
| 2005 | 86.63 Million USD | 39.54% |
| 2004 | 62.08 Million USD | 44.73% |
| 2003 | 42.89 Million USD | -17.14% |
| 2002 | 51.76 Million USD | 20.06% |
| 2001 | 43.11 Million USD | 14.2% |
| 2000 | 37.75 Million USD | 13.35% |
| 1999 | 33.31 Million USD | 31.15% |
| 1998 | 25.4 Million USD | 1.2% |
| 1997 | 25.1 Million USD | 44.25% |
| 1996 | 17.4 Million USD | 112.2% |
| 1995 | 8.2 Million USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 Q1 | 122 Million USD | -1.53% |
| 2023 Q3 | 134.3 Million USD | 6.84% |
| 2023 Q2 | 125.7 Million USD | 3.03% |
| 2022 Q4 | 123.9 Million USD | 16.89% |
| 2022 Q3 | 106 Million USD | -18.21% |
| 2022 Q2 | 129.6 Million USD | 10.86% |
| 2022 Q1 | 116.9 Million USD | 1.65% |
| 2022 FY | 476.4 Million USD | -3.37% |
| 2021 Q4 | 115 Million USD | -3.77% |
| 2021 Q2 | 135.7 Million USD | 10.5% |
| 2021 Q1 | 122.8 Million USD | 14.23% |
| 2021 FY | 493 Million USD | 30.15% |
| 2021 Q3 | 119.5 Million USD | -11.94% |
| 2020 Q3 | 101 Million USD | 78.76% |
| 2020 FY | 378.8 Million USD | -41.73% |
| 2020 Q2 | 56.5 Million USD | -50.4% |
| 2020 Q1 | 113.9 Million USD | -21.72% |
| 2020 Q4 | 107.5 Million USD | 6.44% |
| 2019 Q1 | 168 Million USD | 2.0% |
| 2019 Q2 | 164.8 Million USD | -1.9% |
| 2019 Q3 | 136.6 Million USD | -17.11% |
| 2019 Q4 | 145.5 Million USD | 6.52% |
| 2019 FY | 650.1 Million USD | 0.0% |
| 2018 Q2 | 155.2 Million USD | 3.88% |
| 2018 Q4 | 164.7 Million USD | 7.93% |
| 2018 FY | 650.1 Million USD | 9.19% |
| 2018 Q1 | 149.4 Million USD | -0.13% |
| 2018 Q3 | 152.6 Million USD | -1.68% |
| 2017 Q1 | 152.6 Million USD | 0.33% |
| 2017 Q4 | 149.6 Million USD | 1.63% |
| 2017 FY | 595.4 Million USD | -0.8% |
| 2017 Q3 | 147.2 Million USD | -6.84% |
| 2017 Q2 | 158 Million USD | 3.54% |
| 2016 Q4 | 152.1 Million USD | 10.62% |
| 2016 Q2 | 146.5 Million USD | -2.53% |
| 2016 Q1 | 150.3 Million USD | -1.57% |
| 2016 FY | 600.2 Million USD | 0.62% |
| 2016 Q3 | 137.5 Million USD | -6.14% |
| 2015 Q3 | 147 Million USD | -3.54% |
| 2015 FY | 596.5 Million USD | 3.61% |
| 2015 Q1 | 143.69 Million USD | -1.94% |
| 2015 Q2 | 152.4 Million USD | 6.06% |
| 2015 Q4 | 152.7 Million USD | 3.88% |
| 2014 Q3 | 133.97 Million USD | -15.09% |
| 2014 Q4 | 146.54 Million USD | 9.38% |
| 2014 FY | 575.7 Million USD | -13.95% |
| 2014 Q1 | 156.31 Million USD | -12.15% |
| 2014 Q2 | 157.78 Million USD | 0.94% |
| 2013 Q2 | 152.04 Million USD | 11.68% |
| 2013 Q1 | 136.13 Million USD | 5.32% |
| 2013 FY | 669.01 Million USD | 25.39% |
| 2013 Q4 | 177.92 Million USD | 0.53% |
| 2013 Q3 | 176.98 Million USD | 16.41% |
| 2012 FY | 533.54 Million USD | 23.69% |
| 2012 Q1 | 112.54 Million USD | 5.49% |
| 2012 Q4 | 129.25 Million USD | 11.32% |
| 2012 Q3 | 116.11 Million USD | 0.08% |
| 2012 Q2 | 116.01 Million USD | 3.08% |
| 2011 Q2 | 94.88 Million USD | 4.0% |
| 2011 Q4 | 106.69 Million USD | 11.03% |
| 2011 FY | 431.34 Million USD | 21.38% |
| 2011 Q1 | 91.24 Million USD | 3.22% |
| 2011 Q3 | 96.09 Million USD | 1.27% |
| 2010 FY | 355.37 Million USD | 11.62% |
| 2010 Q3 | 80.84 Million USD | -2.2% |
| 2010 Q2 | 82.66 Million USD | 3.4% |
| 2010 Q1 | 79.95 Million USD | -2.12% |
| 2010 Q4 | 88.39 Million USD | 9.33% |
| 2009 Q1 | 76.25 Million USD | 4.01% |
| 2009 Q4 | 81.68 Million USD | 10.3% |
| 2009 Q3 | 74.06 Million USD | 6.06% |
| 2009 Q2 | 69.82 Million USD | -8.43% |
| 2009 FY | 318.36 Million USD | 12.39% |
| 2008 Q1 | 53.5 Million USD | 9.07% |
| 2008 FY | 283.26 Million USD | -5.98% |
| 2008 Q4 | 73.31 Million USD | 14.81% |
| 2008 Q3 | 63.86 Million USD | -59.53% |
| 2008 Q2 | 157.8 Million USD | 194.95% |
| 2007 Q3 | 40.93 Million USD | 8.07% |
| 2007 Q2 | 37.87 Million USD | 13.42% |
| 2007 Q1 | 33.39 Million USD | 12.79% |
| 2007 FY | 301.28 Million USD | 138.53% |
| 2007 Q4 | 49.05 Million USD | 19.84% |
| 2006 Q2 | 23.96 Million USD | 7.43% |
| 2006 Q1 | 22.3 Million USD | 5.92% |
| 2006 FY | 126.31 Million USD | 45.8% |
| 2006 Q4 | 29.6 Million USD | 16.38% |
| 2006 Q3 | 25.43 Million USD | 6.16% |
| 2005 Q4 | 21.05 Million USD | 9.05% |
| 2005 FY | 86.63 Million USD | 39.54% |
| 2005 Q2 | 20.44 Million USD | 39.4% |
| 2005 Q1 | 14.66 Million USD | 1.08% |
| 2005 Q3 | 19.31 Million USD | -5.53% |
| 2004 Q2 | 11.23 Million USD | 11.84% |
| 2004 Q1 | 10.04 Million USD | -6.1% |
| 2004 Q3 | 12.47 Million USD | 10.98% |
| 2004 Q4 | 14.5 Million USD | 16.33% |
| 2004 FY | 62.08 Million USD | 44.73% |
| 2003 Q1 | 12.72 Million USD | -9.25% |
| 2003 Q2 | 12.42 Million USD | -2.35% |
| 2003 Q3 | 10.91 Million USD | -12.18% |
| 2003 FY | 42.89 Million USD | -17.14% |
| 2003 Q4 | 10.7 Million USD | -1.96% |
| 2002 Q4 | 14.02 Million USD | 11.39% |
| 2002 FY | 51.76 Million USD | 20.06% |
| 2002 Q3 | 12.59 Million USD | 13.61% |
| 2002 Q2 | 11.08 Million USD | 8.54% |
| 2002 Q1 | 10.2 Million USD | -6.42% |
| 2001 Q4 | 10.91 Million USD | -0.08% |
| 2001 FY | 43.11 Million USD | 14.2% |
| 2001 Q1 | 9.41 Million USD | -7.91% |
| 2001 Q2 | 8.6 Million USD | -8.68% |
| 2001 Q3 | 10.91 Million USD | 26.95% |
| 2000 FY | 37.75 Million USD | 13.35% |
| 2000 Q4 | 10.22 Million USD | 7.49% |
| 2000 Q1 | 9.42 Million USD | 17.84% |
| 2000 Q2 | 8.93 Million USD | -5.22% |
| 2000 Q3 | 9.51 Million USD | 6.48% |
| 1999 Q2 | 6.7 Million USD | -2.9% |
| 1999 Q1 | 6.9 Million USD | 16.95% |
| 1999 FY | 33.31 Million USD | 31.15% |
| 1999 Q4 | 8 Million USD | 14.29% |
| 1999 Q3 | 7 Million USD | 4.48% |
| 1998 Q4 | 5.9 Million USD | 1.72% |
| 1998 FY | 25.4 Million USD | 1.2% |
| 1998 Q1 | 6.1 Million USD | 8.93% |
| 1998 Q2 | 6.9 Million USD | 13.11% |
| 1998 Q3 | 5.8 Million USD | -15.94% |
| 1997 Q1 | 3.3 Million USD | 0.0% |
| 1997 Q2 | 8 Million USD | 142.42% |
| 1997 Q3 | 6.4 Million USD | -20.0% |
| 1997 FY | 25.1 Million USD | 44.25% |
| 1997 Q4 | 5.6 Million USD | -12.5% |
| 1996 Q3 | 2.7 Million USD | 12.5% |
| 1996 FY | 17.4 Million USD | 112.2% |
| 1996 Q1 | 2.3 Million USD | 35.29% |
| 1996 Q4 | 3.3 Million USD | 22.22% |
| 1996 Q2 | 2.4 Million USD | 4.35% |
| 1995 Q4 | 1.7 Million USD | 70.0% |
| 1995 FY | 8.2 Million USD | 0.0% |
| 1995 Q3 | 1 Million USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Editas Medicine, Inc. | -99.52 Million USD | 578.659% |
| Dynavax Technologies Corporation | 182.11 Million USD | -161.59% |
| Cara Therapeutics, Inc. | 14.79 Million USD | -3120.224% |
| Walgreens Boots Alliance, Inc. | 26.52 Billion USD | 98.204% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | 9.039% |
| Perrigo Company plc | 1.68 Billion USD | 71.65% |
| Atara Biotherapeutics, Inc. | -313 Thousand USD | 152304.473% |
| Illumina, Inc. | 2.74 Billion USD | 82.638% |
| Thermo Fisher Scientific Inc. | 15.22 Billion USD | 96.871% |
| Nektar Therapeutics | 53.47 Million USD | -790.834% |
| Iovance Biotherapeutics, Inc. | -9.56 Million USD | 5080.138% |
| IQVIA Holdings Inc. | 5.23 Billion USD | 90.907% |
| Heron Therapeutics, Inc. | 10.04 Million USD | -4644.075% |
| Unity Biotechnology, Inc. | -19.69 Million USD | 2518.397% |
| BioMarin Pharmaceutical Inc. | 1.9 Billion USD | 74.984% |
| Waters Corporation | 1.76 Billion USD | 72.95% |
| Biogen Inc. | 7.3 Billion USD | 93.476% |
| Sangamo Therapeutics, Inc. | -45.32 Million USD | 1151.076% |
| Adicet Bio, Inc. | -6.09 Million USD | 7912.398% |
| Evolus, Inc. | 140.52 Million USD | -239.012% |
| bluebird bio, Inc. | -4.03 Million USD | 11921.34% |
| Aclaris Therapeutics, Inc. | -85.21 Million USD | 659.05% |
| Esperion Therapeutics, Inc. | 73.06 Million USD | -552.004% |
| FibroGen, Inc. | 128.9 Million USD | -269.577% |
| Agilent Technologies, Inc. | 3.46 Billion USD | 86.251% |
| Homology Medicines, Inc. | -7.22 Million USD | 6690.123% |
| Geron Corporation | -123.5 Million USD | 485.74% |
| Alnylam Pharmaceuticals, Inc. | 1.51 Billion USD | 68.614% |
| Corbus Pharmaceuticals Holdings, Inc. | -31.16 Million USD | 1628.507% |
| Amicus Therapeutics, Inc. | 362.03 Million USD | -31.591% |
| Regeneron Pharmaceuticals, Inc. | 11.3 Billion USD | 95.785% |
| OPKO Health, Inc. | 318.12 Million USD | -49.752% |
| Viking Therapeutics, Inc. | -292 Thousand USD | 163250.685% |
| Intellia Therapeutics, Inc. | -398.79 Million USD | 219.46% |
| Zoetis Inc. | 5.83 Billion USD | 91.834% |
| Abeona Therapeutics Inc. | 302 Thousand USD | -157648.344% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | 78.037% |
| Exelixis, Inc. | 1.75 Billion USD | 72.896% |
| Vertex Pharmaceuticals Incorporated | 8.6 Billion USD | 94.465% |
| uniQure N.V. | 2.21 Million USD | -21407.901% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | 157327.723% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Axsome Therapeutics, Inc. | 244.53 Million USD | -94.819% |
| Verastem, Inc. | -62 Thousand USD | 768487.097% |
| Imunon, Inc. | -720 Thousand USD | 66266.207% |
| Ionis Pharmaceuticals, Inc. | 778.51 Million USD | 38.806% |
| Sarepta Therapeutics, Inc. | 1.09 Billion USD | 56.413% |
| Neurocrine Biosciences, Inc. | 1.84 Billion USD | 74.212% |
| Corcept Therapeutics Incorporated | 475.89 Million USD | -0.106% |
| Halozyme Therapeutics, Inc. | 636.89 Million USD | 25.199% |
| TG Therapeutics, Inc. | 219.1 Million USD | -117.427% |
| Blueprint Medicines Corporation | 236.58 Million USD | -101.366% |
| Insmed Incorporated | 239.63 Million USD | -98.802% |
| Agios Pharmaceuticals, Inc. | 17.31 Million USD | -2650.736% |
| Incyte Corporation | 3.44 Billion USD | 86.154% |
| Emergent BioSolutions Inc. | 343.9 Million USD | -38.529% |